WO2022221559A3 - Ceramide and sphingomyelin in neurological disorders - Google Patents

Ceramide and sphingomyelin in neurological disorders Download PDF

Info

Publication number
WO2022221559A3
WO2022221559A3 PCT/US2022/024858 US2022024858W WO2022221559A3 WO 2022221559 A3 WO2022221559 A3 WO 2022221559A3 US 2022024858 W US2022024858 W US 2022024858W WO 2022221559 A3 WO2022221559 A3 WO 2022221559A3
Authority
WO
WIPO (PCT)
Prior art keywords
sphingomyelin
ceramide
neurological disorders
assessing
compositions
Prior art date
Application number
PCT/US2022/024858
Other languages
French (fr)
Other versions
WO2022221559A2 (en
WO2022221559A8 (en
Inventor
Rima F. KADDURAH-DAOUK
Augustus John RUSH Jr.
Siamak MAHMOUDIANDEHKORDI
Sudeepa BHATTACHARYYA
Boadie W. DUNLOP
Edward W. CRAIGHEAD
Helen S. Mayberg
Original Assignee
Duke University
Emory University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University, Emory University filed Critical Duke University
Publication of WO2022221559A2 publication Critical patent/WO2022221559A2/en
Publication of WO2022221559A3 publication Critical patent/WO2022221559A3/en
Publication of WO2022221559A8 publication Critical patent/WO2022221559A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/08—Sphingolipids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Described herein are compositions and methods for assessing and modulating ceramide and sphingomyelin in neurological disorders.
PCT/US2022/024858 2021-04-15 2022-04-14 Ceramide and sphingomyelin in neurological disorders WO2022221559A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163175276P 2021-04-15 2021-04-15
US63/175,276 2021-04-15
US202163178978P 2021-04-23 2021-04-23
US63/178,978 2021-04-23

Publications (3)

Publication Number Publication Date
WO2022221559A2 WO2022221559A2 (en) 2022-10-20
WO2022221559A3 true WO2022221559A3 (en) 2022-11-24
WO2022221559A8 WO2022221559A8 (en) 2023-08-03

Family

ID=87474908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/024858 WO2022221559A2 (en) 2021-04-15 2022-04-14 Ceramide and sphingomyelin in neurological disorders

Country Status (1)

Country Link
WO (1) WO2022221559A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049268A1 (en) * 2016-09-08 2018-03-15 Duke University Biomarkers for the diagnosis and characterization of alzheimer's disease
WO2020185580A1 (en) * 2019-03-13 2020-09-17 Duke University Methods and compositions for diagnosing depression

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018049268A1 (en) * 2016-09-08 2018-03-15 Duke University Biomarkers for the diagnosis and characterization of alzheimer's disease
WO2020185580A1 (en) * 2019-03-13 2020-09-17 Duke University Methods and compositions for diagnosing depression

Also Published As

Publication number Publication date
WO2022221559A2 (en) 2022-10-20
WO2022221559A8 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
MX2021013197A (en) Substituted cycloalkyls as modulators of the integrated stress pathway.
UY38685A (en) INTEGRATED TRACK MODULATORS
EP1435946B8 (en) Linked biaryl compounds
AU2016204346A1 (en) Methods and compositions for cell-proliferation-related disorders
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
CR20210500A (en) Heavy chain antibodies binding to psma
WO2019006005A3 (en) Methods and compositions for treating melanoma
JOP20210323A1 (en) Multispecific heavy chain antibodies binding to cd22 and cd3
MX2023004870A (en) Modulators of the integrated stress pathway.
MX2022009762A (en) P2x3 modulators.
AU2016204334A1 (en) Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
EP3952864A4 (en) Compositions and methods for modulating lipid and steroid metabolism
ZA202209970B (en) Neurotoxin compositions for use in treating cardiovascular disorders
PH12021551223A1 (en) Decarboxylase inhibitors for treating parkinson`s disease
WO2022221559A8 (en) Ceramide and sphingomyelin in neurological disorders
EP3893988A4 (en) Neuromodulation therapy for auto-immune and inflammatory disorders
AU2018333275A1 (en) Treatment method
MX2021014484A (en) Progranulin modulators and methods of using the same.
MX2021011609A (en) Modulators of cell surface protein interactions and methods and compositions related to same.
EP3952746A4 (en) Method for assessment of audience attention
EP3735129A4 (en) Compositions and methods for treating neurological and other disorders
AU2021303517A8 (en) System
MX2022002853A (en) Neurotoxin compositions for use in treating gastroparesis.
MX2021009394A (en) Cannabinoid receptor agonists and serine hydrolase enzyme inhibitor based anxiolytic therapeutic product.
EP3979996A4 (en) Methods and formulations for treating vision disorders

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22788951

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 22788951

Country of ref document: EP

Kind code of ref document: A2